Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

22. Mai 2026 03:45 ET | Quelle: Boehringer Ingelheim Limited

China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis

Not intended for UK and US media Therapy approved based on Phase Ib Beamion LUNG-1 trial data, demonstrating robust efficacy (75.7% objective response rate) in treatment-naïve patients1Expedited...
21. Mai 2026 17:00 ET | Quelle: Boehringer Ingelheim Limited

Boehringer Ingelheim’s oncology portfolio shows strong promise across multiple cancers at ASCO 2026

Not intended for US and UK media New patient-reported outcomes data shows improved function and reduced symptom burden with HERNEXEOS® (zongertinib tablets) as an initial treatment option in HER2...
16. April 2026 07:00 ET | Quelle: Boehringer Ingelheim Limited

Beamion LUNG-1 study results for zongertinib in treatment-naïve patients with HER2-mutant advanced NSCLC published in The New England Journal of Medicine

This press release is not intended for US or UK media. Ingelheim, Germany and Ridgefield, Conn. Boehringer Ingelheim today announced that The New England Journal of Medicine (NEJM) published results...
26. Februar 2026 13:50 ET | Quelle: Boehringer Ingelheim Limited

FDA approves HERNEXEOS®, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option

This press release is not intended for UK media HERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as demonstrated in the Beamion LUNG-1 clinical trial1...
01. September 2025 03:05 ET | Quelle: Boehringer Ingelheim Limited

Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

This press release is not intended for UK and US media. HERNEXEOS® (zongertinib tablets) has been approved based on an objective response rate of 71% (N=75), as demonstrated in the Beamion-LUNG 1...
08. August 2025 15:25 ET | Quelle: Boehringer Ingelheim Limited

U.S. FDA grants accelerated approval to Boehringer’s HERNEXEOS® as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

This press release is not intended for UK media. HERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 75% (N=71), as demonstrated in the Beamion-LUNG 1 clinical...